Programme

08:00 Registration Opens DKMS
08:00 – 09:00       Closed Session

09:00 – 12:30       Open Session
09:00 -10:00 SYMPOSIUM DR REDDY’S
Topic: Advancing Treatment of recurrent/metastatic Nasopharyngeal Carcinoma: Integrating Immunotherapy into Clinical Practice

Speaker: Dr. Chandrakanth M V

Session 1:  Joint Plenary : Diagnostics in Cancer

Chairs: Prof Georgia Demetriou
Prof  Estelle Verburgh

10.20-10:30 Opening

Dr Devan Moodley and Dr Justin Du Toit
10:30-11:00 Liquid biopsies in 2026
Speaker: Dr Kusha Kalideen |Lancet
11:00-11:30 The place of genetic testing in cancer

Speaker: tbc
11:30-12:00 Risk Adapted therapy in EBC

Speaker: Dr William Audeh

Sponsored by Genomics
12:00-12:30 The molecular footprint of cytotoxic therapies

Speaker: Rachel Viava | Lancet

12:30-13:20 LUNCH SYMPOSIUM : ASTRA ZENECA
Topic: HER2
Speaker: Prof Mattea Reinisch
13:30-15:30  Session 2: Breast Track
Chairs:		 Session 2: Optimising the Recipient

Chairs: Dr Justin Du Toit & Dr Candice Hendricks

13:30-14:00 Topic: CDK4/6i in EBC What when and whom?

Speaker: Dr John Crown
 
 

Topic: Model-based dosing of ATG for better survival after allo transplantation

Speaker: Professor Jan Jaap de Boelens – Chief of the Paediatric Transplant and Cellular Therapy Service (TCT) at Memorial Sloane Kettering, New York, USA

Sponsored by DKMS

14:00-14:30 Topic: ADC,s in BC. Where is it best used?

Speaker: Prof Mattea Reinisch

Topic: Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis

Dr Donal McLornan – University college London, UK

Sponsored by Novartis

14:30-15:00 Case 1:
1 EBC 1 MBC
Q and A 		Topic: tbc

Speaker:  Prof Roberto Mina

15:00- 15:30 Case 2:
1 EBC 1 MBC
Q and A
 		 Topic: Haplo SCT strategies in resource limited settings

Speaker: Dr Mohana Reddy – Sankalp foundation, India Sponsored by: DKMS

15:30-16:00 REFRESHMENT BREAK REFRESHMENT BREAK
16:00-16:30 Topic: What’s new in Her2 amplified disease?

Speaker: Dr Mark Verril

Topic: ‘real world’ experience of JAK inhibitors, splenomegaly management and novel agents in myelofibrosis transplant

Speaker: Dr Donal McLornan – UCL, London

Sponsored by Novartis
16:30-17:00 Topic: Optimal management of the Her2 low patient

Speaker: tbc 

Topic: (GRAPPA) Graft vs host disease prophylaxis in MUD allo: a RCT comparing PTCy vs ATG

Speaker: Dr Judith Schaffrath – Martin Luther University Halle-Wittenberg, Germany

Sponsored by DKMS

17:00-18:00 Case 1: Her2 positive 1 Her2 low
Q and A 		Topic: tbc

Speaker: Prof Elias Jabbour

Sponsored: Aspen Pharmacare

Case 2: Her2 positive 1 Her2 low
Q and A		 Topic: Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

Speaker: Dr Judith Schaffrath – Martin Luther University Halle-Wittenberg, Germany

Sponsored by DKMS

18:00-18:30 SASMO AGM  SASCeTS AGM  
18:30-21:30 Exhibitors Welcome | Networking Cocktail
07:00 Registration & Exhibition Opens
07:00-07:50 SYMPOSIUM : NOVARTIS
Topic:  tbc
Speaker: Dr John Crown 		 
Session 3: Joint Plenary 
Chairs: 
07:50-08:00 Opening of Plenary 
08:00-08:30   Falkson Honorary Lecture
Speaker: tbc
08:30-09:00 A bone marrow transplant registry for South Africa
Speaker: Prof Estelle Verburgh
09:00-09:30 Essentials of setting up research units in SA?
Speaker: Prof Paul Ruff
09:30-10:00 Fertility Lecture
10:00-10:50 REFRESHMENT BREAK
10:00-10:50 SYMPOSIUM J & J                   
Topic: Prostate
Speaker: tbc 		SYMPOSIUM ASTRA ZENECA
Topic: Eculizumab in thrombotic micro-angiopathy    post-transplant
Speaker: Dr Regis da Latour, Paris, France
Chair: Dr Justin Du Toit
10:50-13:00 Session 4:
SASMO SASCETS SASOPh – PHARMACISTS SASREG NURSES SYMPOSIUM
Session 4: Uro Genital Track
Chairs: 		Session 4:
Donor track
Chairs:
10:50-11:20   Topic: The latest developments in the treatment of metastatic Renal Cell Carcinoma.
Speaker: Prof Manuela Schmidinger		 Topic: Donor selection beyond HLA: focus on donor age
Speaker:
Prof. Dr Tobias Holderried – Bonn, Germany

Sponsored by DKMS
 
11:20-11:50 Topic: PARP
Speaker: tbc		 Topic: Allo-HCT in Sickle cell disease
Speaker: Julie Makani

Sponsored by DKMS

11:50:12: 20 Topic: Prostate
Speaker: tbc 		Topic: Optimising donor outcomes
Speaker: Jay Feinberg – CEO, of Gift of Life Marrow Registry, New York

Sponsored: by SABMR
12:20-12:50 Topic: ARPi’s in Metastatic Prostate Cancer Topic: Duffy agnostic decision making (donors)
Speaker: Tanya Glatt
12:50-13:00 Q and A Q and A
13:00-14:00 LUNCH
13:00-13:50 SYMPOSIUM – ROCHE
Topic: Advancing Consensus in HER2+ Early Breast Cancer Treatment: Integrating Economic Impact and Health Equity in South Africa
Speaker: tbc  		 SYMPOSIUM J& J
Topic: Into the Future: The next Generation of Myeloma Management 
Speaker: Prof Roberto Mina
14:00-17:00 Session 5:
SASMO
Lung
Chairs: 		SASCETS
Cell & Gene Therapy SA
Chairs: 		SASOPh – PHARMACISTS SASREG NURSES SYMPOSIUM
14:00-14:30 Topic: Rare Lung Cancer Mesothelioma Thymic NET
Speaker: tbc		 Topic: CAR-NK cells (immunity Bio)
Speaker: Lennie Sender & Jackie Thomson
14:30-15:00 Topic: The evolution of lung cancer treatment
Speaker:Dr Lizza Hendricks
 		 Topic: Access to CGT in SA
Speaker: Prof Candice Hendricks
15:00-15:30 Panel Discussion
Topic: How to improve lung cancer care in Africa 		Topic: CAR T cell trial ACTLife.
Speaker: D. Brittain
15:30-16:00 REFRESHMENT BREAK
16:00-18:00   Session 6: Innovation in Oncology
Chairs:
16:00-16:30 Topic: Skin cancer
Speaker: Dr Teresa Amaral
 		 Topic: ATT progress in South Africa
Speaker: Elke Neujahr, CEO DKMS 		   
16:30-17:00 Topic: Innovation in Cancer Treatment
Speaker: tbc 		Topic: Allo-HCT for children with inborn errors
Speaker: Prof Michael Albert, DKMS   
17:00-18:00 Proffered papers Proffered papers
19:30-22:30 CONFERENCE DINNER
  Session 7: Joint Plenary
Chairs:
08:30-08:40 Opening
08:40-09:00 How does NICE assess funding for innovative products
Speaker: tbc
09:00-09:30 AI in Oncology
Speaker: Dr Hemmel Amrania
09:30-10:00  VZV Vaccinations in Oncology patients
Speaker: Dr Jeremy Nel  
10:00-11:00 REFRESHMENT BREAK 
10:00-10:50 SYMPOSIUM ROCHE  
Topic: Breaking Barriers in Lung Cancer: Advanced Strategies for Managing Difficult-to-Treat Patients
Speaker: tbc
 		 SYMPOSIUM GSK
Topic: V Vaccines post-haematopoietic transplant
Speaker: Dr Jeremy Nel
 
11:00-12:00 SASMO
Session 6: Female Genital track
Chairs: 		SASCeTS:
Session 6: Pre Tx Optimisation & Post Transplant Complications
Chairs:
11:00-11:30 Topic: Ovarian Cancer
Speaker: tbc 		Topic: Belumosudil use for chronic GVHD
Speaker: Professor Jan Jaap de Boelens – MSK, NY, USA

Sponsored by DKMS

11:30-12:00 Topic: Endometrial Cancer
Speaker: tbc
 		 Topic: Transfusion medicine topic
Speaker: Professor Matt Seftel
12:00 Close Close

Adcock Ingram is a Proudly South African company. Adcock Ingram manufactures, markets, sells and distributes a wide range of products. The diversified portfolio includes an extensive portfolio of branded and generic prescription medicines.

www.adcock.com

Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine and Eurasian countries, and Latin America.

We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing.

https://acino.swiss/

M-ZA-00002893 Expiration Date 07/03/2027

Roche Pharmaceuticals: Leading the Charge in Oncology

Roche is one of the world’s largest biotechnology company and has spent over 125 years redefining cancer care through a fusion of innovative therapies and precision medicine1.In Africa, Roche is one of the primary drivers of oncology advancements, leveraging a vast clinical trial network to deliver targeted treatments for HER2-positive breast cancer and now incorporating the lung cancer2.


Central to its regional mission is the Africa Breast Cancer Ambition, a bold initiative to rewrite the continent's survival narrative. Currently, only 5 in 10 African women survive breast cancer; Roche aims to increase this to 8 in 103 by 20404. To achieve this, Roche is committed to three critical pillars:

  • Early Detection: Increasing stage I/II diagnoses from 30% to 60%.5
  • Faster Diagnosis: Reducing the journey from symptoms to treatment to just 60 days.6
  • Treatment Access: Ensuring 80% of patients receive the standard of care.7

Through these interventions, Roche is dedicated to doing now what patients need next, pioneering an innovative pipeline to improve clinical outcomes and extend the lives of patients in South Africa.

https://www.roche.co.za/about


Roche Products (Pty) Ltd, P O Box 1469, Halfway House, 1685. Tel. +27-11-504-4746 Registration No. 1947/027044/07 Building E, Hertford Office Park, 90 Bekker Road, Vorna Valley, Midrand, 1686 Directors: R. Ferraro (Chairman) (Swiss) Dr S.D. Diale T.G. (South Africa) Renwick (British)

1 Roche South Africa. About Roche [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: About Roche ZA

2 Roche. A new era of healthcare in Africa with AMA [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: A new era of healthcare in Africa with AMA

3 Roche. African Breast Cancer Ambition (ABCA) [Internet; cited 2026 Mar 2]. Available from: Africa Breast Cancer Ambition

4 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

5 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

6 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

7 Roche Africa. Working together to help more women in Africa survive breast cancer [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: Working together to help more women in Africa survive breast cancer